Research programme: CD40 inhibitors - Apoxis
Latest Information Update: 23 Nov 2006
At a glance
- Originator Apoxis
- Class
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 23 Nov 2006 No development reported - Preclinical for Immunological disorders in Switzerland (unspecified route)
- 28 Jun 2004 Preclinical trials in Immunological disorders in Switzerland (unspecified route)